Jazz Pharmaceuticals plc – (NASDAQ:JAZZ)’s share price dropped 1.1% during trading on Tuesday . The stock traded as low as $133.83 and last traded at $134.08, with a volume of 286,286 shares trading hands. The stock had previously closed at $135.51.

JAZZ has been the subject of several research reports. Zacks Investment Research upgraded Jazz Pharmaceuticals plc – from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. Mizuho upgraded Jazz Pharmaceuticals plc – from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $137.00 to $193.00 in a research report on Wednesday, May 11th. Leerink Swann restated a “buy” rating on shares of Jazz Pharmaceuticals plc – in a research report on Wednesday, May 11th. Piper Jaffray Cos. restated a “buy” rating and set a $186.00 price objective on shares of Jazz Pharmaceuticals plc – in a research report on Thursday, May 12th. Finally, SunTrust Banks Inc. restated a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Jazz Pharmaceuticals plc – in a research report on Thursday, June 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $185.25.

The company’s 50 day moving average price is $142.31 and its 200 day moving average price is $139.30. The stock has a market capitalization of $8.16 billion and a PE ratio of 23.69.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.80 by $0.17. The firm earned $381 million during the quarter, compared to analysts’ expectations of $376.40 million. During the same period in the prior year, the firm earned $2.41 EPS. The company’s quarterly revenue was up 14.2% on a year-over-year basis. Equities analysts expect that Jazz Pharmaceuticals plc – will post $10.08 EPS for the current fiscal year.

In other news, SVP Paul Treacy sold 1,292 shares of the business’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $137.47, for a total value of $177,611.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Russell J. Cox sold 4,000 shares of the business’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $148.66, for a total value of $594,640.00. The disclosure for this sale can be found here.

Several large investors recently added to or reduced their stakes in the stock. BlackRock Advisors LLC raised its stake in Jazz Pharmaceuticals plc – by 119.4% in the fourth quarter. BlackRock Advisors LLC now owns 311,095 shares of the specialty pharmaceutical company’s stock worth $43,728,000 after buying an additional 169,312 shares during the period. RS Investment Management Co. LLC raised its stake in Jazz Pharmaceuticals plc – by 13.2% in the fourth quarter. RS Investment Management Co. LLC now owns 359,125 shares of the specialty pharmaceutical company’s stock worth $50,479,000 after buying an additional 41,992 shares during the period. Finally, I.G. Investment Management LTD. raised its stake in Jazz Pharmaceuticals plc – by 0.5% in the fourth quarter. I.G. Investment Management LTD. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $2,837,000 after buying an additional 108 shares during the period.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.